• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis

    Thumbnail
    View/Open
    Research article (1.106Mb)
    Date
    2009-08-23
    Author
    Zwang, Julien
    Olliaro, Piero
    Barennes, Hubert
    Bukirwa, Hasifa
    Karema, Corine
    Bonnet, Maryline
    Yeka, Adoke
    Brasseur, Philippe
    Cohuet, Sandra
    D'Alessandro, Umberto
    Djimdé, Abdulaye
    Guthmann, Jean-Paul
    Hamour, Sally
    Ndiaye, Jean-Louis
    Mårtensson, Andreas
    Rwagacondo, Claude
    Sagara, Issaka
    Same-Ekobo, Albert
    Sirima, Sodiomon B.
    van den Broek, Ingrid
    Metadata
    Show full item record
    Abstract
    Background: Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely used artemisinin-based combination therapy (ACT). It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy. Methods: An individual patient data (IPD) analysis was conducted on efficacy outcomes in 26 clinical studies in sub-Saharan Africa using the WHO protocol with similar primary and secondary endpoints. Results: A total of 11,700 patients (75% under 5 years old), from 33 different sites in 16 countries were followed for 28 days. Loss to follow-up was 4.9% (575/11,700). AS&AQ was given to 5,897 patients. Of these, 82% (4,826/5,897) were included in randomized comparative trials with polymerase chain reaction (PCR) genotyping results and compared to 5,413 patients (half receiving an ACT). AS&AQ and other ACT comparators resulted in rapid clearance of fever and parasitaemia, superior to non-ACT. Using survival analysis on a modified intent-to-treat population, the Day 28 PCR-adjusted efficacy of AS&AQ was greater than 90% (the WHO cut-off) in 11/16 countries. In randomized comparative trials (n = 22), the crude efficacy of AS&AQ was 75.9% (95% CI 74.6–77.1) and the PCR-adjusted efficacy was 93.9% (95% CI 93.2–94.5). The risk (weighted by site) of failure PCR-adjusted of AS&AQ was significantly inferior to non-ACT, superior to dihydroartemisinin-piperaquine (DP, in one Ugandan site), and not different from AS+SP or AL (artemether-lumefantrine). The risk of gametocyte appearance and the carriage rate of AS&AQ was only greater in one Ugandan site compared to AL and DP, and lower compared to non-ACT (p = 0.001, for all comparisons). Anaemia recovery was not different than comparator groups, except in one site in Rwanda where the patients in the DP group had a slower recovery. Conclusion: AS&AQ compares well to other treatments and meets the WHO efficacy criteria for use against falciparum malaria in many, but not all, the sub-Saharan African countries where it was studied. Efficacy varies between and within countries. An IPD analysis can inform general and local treatment policies. Ongoing monitoring evaluation is required.
    URI
    http://www.malariajournal.com/content/8/1/203
    http://hdl.handle.net/10570/1385
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV